Kinsip: From Spirits to Sanitizer Custom Case Solution & Analysis

1. Evidence Brief: Case Extraction

Financial Metrics

• Revenue Impact: The closure of the tasting room and onsite retail due to COVID-19 lockdowns resulted in an immediate loss of nearly 100 percent of direct-to-consumer sales (Paragraph 4).
• Product Pricing: Premium spirits typically retail between 40 and 60 dollars per bottle, whereas hand sanitizer market rates fluctuated during the shortage but offered significantly lower margins per unit (Exhibit 1).
• Input Costs: Bulk ethanol prices increased by approximately 20 to 30 percent as global demand surged in March 2020 (Paragraph 12).
• Capital Investment: Retooling the bottling line for sanitizer required minimal upfront capital but diverted labor from aging-stock management (Paragraph 15).

Operational Facts

• Production Capacity: The distillery operates on a farm-based system with limited fermentation tank space (Paragraph 6).
• Regulatory Shift: Health Canada expedited site licenses and product licenses for hand sanitizer production, reducing the approval window from months to days (Paragraph 9).
• Supply Chain: Shortages were identified in 250ml and 500ml plastic bottles and pump dispensers, forcing the use of standard 750ml glass spirit bottles for sanitizer (Paragraph 14).
• Distribution: Shifted from LCBO and onsite retail to direct delivery to hospitals, long-term care homes, and local essential services (Paragraph 11).

Stakeholder Positions

• Jeremiah Soucie (CEO): Focused on business continuity and maintaining the workforce while serving the community (Paragraph 3).
• Maria Hristova and Sarah Waterston (Partners): Concerned about the long-term dilution of the premium brand image if the distillery becomes known primarily for sanitizer (Paragraph 18).
• Local Community: High expectation for the distillery to provide essential supplies during the shortage (Paragraph 5).
• Health Canada: Acting as a temporary facilitator rather than a strict regulator during the emergency period (Paragraph 9).

Information Gaps

• Specific net profit margin comparison between a liter of gin and a liter of hand sanitizer.
• Duration of the temporary Health Canada regulatory exemptions.
• Contractual obligations with existing grain and botanical suppliers during the pivot.

2. Strategic Analysis

Core Strategic Question

• How can Kinsip utilize its distillation infrastructure to survive the COVID-19 retail shutdown without permanently devaluing its premium craft brand or depleting resources required for long-term spirit aging?

Structural Analysis

The sudden regulatory shift by Health Canada removed the primary barrier to entry in the sanitizer market. However, the threat of substitutes is extreme as large-scale industrial chemical producers can achieve economies of scale that Kinsip cannot match once supply chains stabilize. The current competitive advantage is local proximity and immediate availability, not cost leadership. The value chain has shifted from a focus on flavor profile and brand experience to a focus on speed to market and high-volume distribution.

Strategic Options

Option 1: The Community Bridge. Produce sanitizer at cost for local frontline workers while maintaining a small-scale spirits production for online sales.
Rationale: Protects brand equity and fulfills social responsibility.
Trade-offs: Limits cash flow and does not fully utilize idle labor.
Resources: Existing fermentation tanks and local delivery vehicles.

Option 2: Full Industrial Pivot. Maximize sanitizer production for commercial sale to corporate and government buyers.
Rationale: Generates maximum immediate cash flow to offset lost spirits revenue.
Trade-offs: Risks equipment wear and brand dilution; creates a difficult transition back to premium spirits.
Resources: External ethanol sourcing and high-speed bottling lines.

Option 3: The Hybrid Premium Model. Produce sanitizer in Kinsip-branded glass bottles as a limited-edition product, sold alongside spirits.
Rationale: Maintains premium positioning while addressing market demand.
Trade-offs: High packaging costs for a commodity product.
Resources: Standard glass bottle inventory and existing label designs.

Preliminary Recommendation

Kinsip should adopt Option 1. The sanitizer market will commoditize rapidly as industrial players catch up. Kinsip’s long-term value resides in its identity as a craft distillery. Using the pivot as a community-service initiative builds brand loyalty that will pay dividends when the tasting room reopens. Financial survival should be managed through government wage subsidies and online spirit sales rather than attempting to compete in the low-margin industrial chemical space.

3. Implementation Roadmap

Critical Path

• Week 1: Secure Health Canada temporary site and product licenses.
• Week 1: Source USP-grade ethanol or high-proof neutral grain spirits to bypass the slow fermentation stage.
• Week 2: Retool the bottling line for liquid sanitizer, which has a different viscosity than spirits.
• Week 2: Establish a direct-to-institution ordering portal to bypass traditional retail bottlenecks.
• Week 3: Launch a Buy-One-Give-One campaign to link spirit sales with sanitizer donations.

Key Constraints

• Input Availability: The scarcity of plastic bottles and pumps is a hard constraint. Using glass bottles increases costs and creates safety risks in clinical environments.
• Labor Safety: Distilling high-proof alcohol for sanitizer increases fire risks and requires strict adherence to safety protocols in a facility designed for lower-volume production.

Risk-Adjusted Implementation Strategy

The strategy assumes a 12-week peak demand window. Production must remain modular. Kinsip should not invest in permanent sanitizer-specific machinery. Instead, use manual filling stations for small batches. If industrial supply returns sooner than expected, Kinsip must be prepared to cease sanitizer production within 48 hours to avoid holding unsellable commodity inventory. Contingency planning includes a shift to high-proof spirit production that can be either sold as vodka or converted to sanitizer depending on the market signal at the time of bottling.

4. Executive Review and BLUF

BLUF

Kinsip must pivot to hand sanitizer production immediately, but only as a temporary tactical maneuver to maintain cash flow and community relevance. The distillery should cap sanitizer production at 50 percent of total capacity to ensure that aging spirits programs—the core of the business value—are not neglected. Success depends on treating sanitizer as a public relations and community support tool rather than a new core business line. Exit the sanitizer market the moment industrial supply stabilizes to avoid a low-margin trap that erodes the premium brand.

Dangerous Assumption

The analysis assumes that the brand equity gained from community service will outweigh the operational distraction. If the pandemic duration exceeds 18 months, the diversion of labor from spirits aging will create a revenue hole in three years that sanitizer profits cannot fill.

Unaddressed Risks

• Liability Risk: Producing a health product carries significant legal exposure if the formula fails to meet efficacy standards or causes adverse reactions. Probability: Medium. Consequence: High.
• Equipment Degradation: High-proof ethanol production at scale may accelerate wear on seals and pumps not designed for continuous industrial chemical throughput. Probability: High. Consequence: Medium.

Unconsidered Alternative

The team did not consider a white-label partnership. Kinsip could have provided the distillation expertise to a larger chemical distributor in exchange for a fixed fee, offloading the bottling, distribution, and liability risks while maintaining steady cash flow.

Verdict

APPROVED FOR LEADERSHIP REVIEW